Risk factors
Aktis Oncology (AKTS) risk factors
Item 1A of every Aktis Oncology, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors129 risks
Aktis Oncology focuses on developing targeted radiopharmaceuticals, relying heavily on licensing agreements and partnerships like Eli Lilly. The company faces ongoing financial losses and relies on recent IPO proceeds to fund operations into 2029.
Filed Mar 30, 2026